Milan, June 13, 2014 – Promising results from phase-I study for CLL patients will be presented by Dr John Seymour.

Milan, June 13, 2014 – Dr Zafer Başlar will present the results of a multicenter study that was conducted in Turkey to evaluate the efficacy and tolerability of generics for CML patients.

Milan, June 13, 2014 – Dr Nicola Gökbuget will explain also on behalf of Max Topp, the results of two abstracts that will be presented during the 19th Congress of EHA about the treatment of ALL.

Milan, June 13, 2014 – New possible treatment options for thalassemia patients will be presented by Dr Olivier Hermine at the 19th Congress of EHA.

Milan, June 13, 2014 – Results from a large international study on pediatric ITP will be presented at the 19th Congress of EHA by Dr John Grainger.

Milan, June 13, 2014 – Dr Alessandro Vannucchi will present the promising results of a Phase III trial for polycythemia vera patients.

Multiple myeloma (MM), a proliferation (growth) of malignant plasma cells in the bone marrow destroying bones, accounts for 10% of all hematologic malignancies. Approximately 45.000 new cases are diagnosed each year together in the US and Europe. MM is mainly a disease of elderly people with age at diagnosis between 65-70 years.

The dramatic improvement in outcome for children with acute lymphoblastic leukemia is one of the major achievements in hematology in the last 40 years. However, while 90% of children with this disease can now be cured, the outlook has not been so good for the less common type of childhood leukemia, acute myeloid leukemia (AML). Although only 1 in 7 children with leukemia have AML, half of these children will die from their disease. The challenge now is to harness the new developments in genomics to improve the outcome for these children.

Blood cancers (leukemias) are life-threatening diseases that can devastate the lives of patients and their families. Great progress has been made in treatments to improve the survival of these otherwise invariably fatal conditions. Major advances in the understanding of leukemia genetics for genome sequencing of individual patients has taken us one step further towards realizing personalized medicine for many patients.

The International Society on Thrombosis and Haemostasis (ISTH) partners with thrombosis related organizations from every continent to launch World Thrombosis Day focused on single cause of top 3 cardiovascular deaths worldwide.

EHA endorses and supports the initiative for this World Thromobis Day.

The European Hematology Association is organizing its 19^th Congress in Milan, Italy- June 12-15, 2014.

Following last year’s successful introduction, the EHA congress program will be complemented by a dedicated advocacy track. This track combines all patient and policy related sessions into one comprehensive full-day program on Saturday.

The Board of the European Hematology Association (EHA) has the pleasure to cordially invite you, as a member of the press, to the 19th Congress of EHA.More than 9,500 participants from around the world are expected at the upcoming 19th Congress of the European Hematology Association at the MiCo - Milano Congressi in Milan, Italy from June 12-15, 2014.

The European School of Haematology (ESH) hosted an international meeting on haematological disorders in the elderly in Barcelona from November 6 to 7, 2013.
Chairs of the meeting were L. Balducci, M. Björkholm, and P. Fenaux. The local organizer: E. Montserrat. The meeting was organized to provide a comprehensive review of the aspects to be considered when managing elderly patients with a variety of hematological disturbances.

Report the unavailability of Hematology Medicines to EHA today!

In the course of one day – December 11, 2013 – two calls for applications and expressions of interest were published that are of interest to researchers in hematology.